Real-World study reveals how long lung fibrosis patients stick with treatment
NCT ID NCT06485635
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This completed study in France tracked over 10,000 people with idiopathic pulmonary fibrosis to see how long they continued taking antifibrotic drugs (nintedanib or pirfenidone). The goal was to measure the percentage still on treatment after 30 months and identify factors linked to stopping early. The study did not test new treatments but aimed to improve real-world care.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Nintedanib and Pirfenidone
- What this could lead to
- If successful, this could help doctors understand why some patients stop treatment and find ways to improve long-term care for lung fibrosis.
- What could go wrong
- This is an observational study, not a treatment trial. It only measures persistence, not whether the drugs work or are safe.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
10,646 people
The number who actually took part.
- Started
-
Oct 2024
- Finished
-
Apr 2026
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
All patients with a reimbursement of AF treatment between 2018 and 2022 will be included for analysis.
- Ages
-
Children (under 18), adults (18 to 64) and older adults (65 and over)
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion criteria: All patients with a reimbursement of AF treatment between 2018 and 2022 will be included for analysis. Exclusion criteria: No exclusion criteria will be applied.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Idiopathic pulmonary fibrosis are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Clinityx
Boulogne-Billancourt, 92100, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Patients and families build a living database of pulmonary fibrosis
- Can pulmonary fibrosis patients pull hard enough for their inhalers?
- Can a thousand patient records unlock better care for a rare lung disease?
- Sharper CT scans may solve a lung disease diagnostic puzzle
- Can we untangle the overlap of lung diseases? a new study aims to find out
- A blood test that could predict who survives a lung disease crisis?